SEC Company Response from REGENERX BIOPHARMACEUTICALS INC (RGRX) (CIK 0000707511) — Aug 9, 2005
REGENERX BIOPHARMACEUTICALS INC (RGRX) (CIK 0000707511)
Date: Aug. 9, 2005 · CIK: 0000707511 · Accession: 0001193125-05-162050
AI Filing Summary & Sentiment
File numbers found in text: 333-125861
Letter
Division of Corporation Finance Re: RegeneRx Biopharmaceuticals, Inc. Registration Statement on Form S-3 Commission File No. 333-125861
Dear Mr. Riedler:
Pursuant to Rule 461 of Regulation C, and in connection with the above-referenced Registration Statement, RegeneRx Biopharmaceuticals, Inc. (the “Company”) hereby requests that said Registration Statement, as amended, be declared effective at 4:30 p.m., Eastern Time, on August 9, 2005, or as soon thereafter as practicable.
The Company hereby further acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please telephone Joseph G. Passaic, Jr. or Philip G. Feigen at the law firm of Patton Boggs LLP at (202) 457-6000.
Very truly yours,
/s/ J.J. FINKELSTEIN
Show Raw Text
CORRESP 1 filename1.htm Letter of Correspondance 3 Bethesda Metro Center Suite 630 Bethesda, MD 20814 Phone: 301.280.1992 Fax: 301.280.1996 August 9, 2005 Jeffrey Riedler Assistant Director Division of Corporation Finance U.S. Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549 Re: RegeneRx Biopharmaceuticals, Inc. Registration Statement on Form S-3 Commission File No. 333-125861 Dear Mr. Riedler: Pursuant to Rule 461 of Regulation C, and in connection with the above-referenced Registration Statement, RegeneRx Biopharmaceuticals, Inc. (the “Company”) hereby requests that said Registration Statement, as amended, be declared effective at 4:30 p.m., Eastern Time, on August 9, 2005, or as soon thereafter as practicable. The Company hereby further acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions regarding this request, please telephone Joseph G. Passaic, Jr. or Philip G. Feigen at the law firm of Patton Boggs LLP at (202) 457-6000. Very truly yours, /s/ J.J. FINKELSTEIN J.J. Finkelstein President and Chief Executive Officer (Principal Executive Officer)